Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada

Journal of Medical Economics

Volumn 19, Issue 2, 2016, Pages 181-192

  Moshyk, A ^a   Martel, M J ^a   Tahami Monfared, A A ^a   Goeree, R ^b  

^a Market Access and Public Affairs   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Canada; Chronic hepatitis C; Cost effectiveness; Daclatasvir; Genotype 3; Pegylated interferon; Sofosbuvir

Indexed keywords

DACLATASVIR; PEGINTERFERON; RIBAVIRIN; SOFOSBUVIR; ANTIVIRUS AGENT; BMS-790052; IMIDAZOLE DERIVATIVE;

ADULT; ANEMIA; ARTICLE; CANADA; CHRONIC HEPATITIS C; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG WITHDRAWAL; END STAGE LIVER DISEASE; FEMALE; GENOTYPE; HEPATITIS C VIRUS GENOTYPE 3; HIDDEN MARKOV MODEL; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SENSITIVITY ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME; AGED; COMBINATION DRUG THERAPY; COST BENEFIT ANALYSIS; DRUG EFFECTS; ECONOMICS; GENETICS; HEALTH CARE COST; HEPACIVIRUS; HEPATITIS C, CHRONIC; MARKOV CHAIN;

ADULT; AGED; ANTIVIRAL AGENTS; CANADA; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; FEMALE; HEALTH CARE COSTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; MALE; MARKOV CHAINS; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; SOFOSBUVIR;

EID: 84955372409     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2015.1106546     Document Type: Article

References (60)

1. Public Health Agency of Canada. Hepatitis C: Get the facts. You can have it and not know it. Ottawa. 2012. http://www.phac-Aspc.gc.ca/hepc/pubs/getfacts-informezvous/index-eng.php. Accessed February 5, 2015
2. Public Health Agency of Canada. Hepatitis C Information for Health Professionals. Ottawa. 2008. http://www.phac-Aspc.gc.ca/hepc/pubs/ihp-ips/index-eng.php. Accessed October 10, 2014
3. Public Health Agency of Canada. Hepatitis C-Quick Facts. Ottawa. 2014. http://www.phac-Aspc.gc.ca/hepc/index-eng.php. Accessed October 10, 2014
4. Centers for Disease Control and Prevention. Hepatitis C FAQs for Health Professionals. Atlanta, GA. 2014. http://www.cdc.gov/hepatitis/hcv/hcvfaq.htm. Accessed October 10, 2014
5. Planas R, Balleste B, Alvarez MA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol 2004; 40: 823-30
6. Tsoulfas G, Goulis I, Giakoustidis D, et al. Hepatitis C and liver transplantation. Hippokratia 2009; 13: 211-15
7. Hsu PC, Federico CA, Krajden M, et al. Health utilities and psychometric quality of life in patients with early-And late-stage hepatitis C virus infection. J Gastroenterol Hepatol 2012; 27: 149-57
8. Ly KN, Xing J, Klevens RM, et al. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156: 271-8
9. Public Health Agency of Canada. Hepatitis C in Canada: 2005-2010 Surveillance Report. Ottawa. 2011. http://publications.gc.ca/collections/collection-2012/aspc-phac/HP40-70-2012-eng.pdf. Accessed August 19, 2014
10. Razavi H, Waked I, Sarrazin C, et al. The present and future disease burden of hepatitis C virus (HCV) infection with todays treatment paradigm. J Viral Hepat 2014; 21 (1 Suppl): 34-59
11. Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74
12. Chen J, Florian J, Carter W, et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 2013; 144: 1450-5
13. Martinot-Peignoux M, Stern C, Maylin S, et al. Twelve weeks post-Treatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology 2010; 51: 1122-6
14. U.S. Food and Drug Administration. Guidance for Industry. Chronic Hepatitis C Virus Infection: developing direct-Acting antiviral drugs for treatment. Silver Spring, MD. 2013. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM225333.pdf. Accessed August 21, 2015
15. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014;60:392-420
16. Bruggmann P, Berg T, Ovrehus AL, et al. Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat 2014; 21 (1 Suppl): 5-33
17. Chaudhary R, Tepper M, Eisaadany S, et al. Distribution of hepatitis C virus genotypes in Canada: Results from the LCDC Sentinel Health Unit Surveillance System. Can J Infect Dis 1999; 10: 53-6
18. Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 2014; 59: 318-27
19. Manns MP, von Hahn T. Novel therapies for hepatitis C-one pill fits all? Nat Rev Drug Discov 2013; 12: 595-610
20. Tapper EB, Afdhal NH. Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3. J Viral Hepat 2013; 20: 669-77
21. Krahn M, Wong JB, Heathcote J, et al. Estimating the prognosis of hepatitis C patients infected by transfusion in Canada between 1986 and 1990. Med Decis Mak 2004; 24: 20-9
22. Krahn MD, John-Baptiste A, Yi Q, et al. Potential cost-effectiveness of a preventive hepatitis C vaccine in high risk and average risk populations in Canada. Vaccine 2005; 23: 1549-58
23. El Saadany S, Coyle D, Giulivi A, et al. Economic burden of hepatitis C in Canada and the potential impact of prevention. Results from a disease model. Eur J Health Econ 2005; 6: 159-65
24. Remis RS. Modelling the Incidence and Prevalence of Hepatitis C Infection and its Sequelae in Canada, 2007 [Internet]. Ottawa: Public Health Agency of Canada, 2009. http://www.phac-Aspc.gc.ca/sti-its-surv-epi/model/pdf/model07-eng.pdf. Accessed August 19, 2015
25. Werb D, Wood E, Kerr T, et al. Treatment costs of hepatitis C infection among injection drug users in Canada, 2006-2026. Int J Drug Policy 2011; 22: 70-6
26. Dryden DM, Doucette K, Tandon P, et al. Granulocyte-colony stimulating factor for antiviral-Associated neutropenia: systematic review and economic evaluation [Internet]. Ottawa: Canadian Agency for Drugs and Technologies in Health, 2008. http://www.cadth.ca/media/pdf/H0473-Granulocyte-Colony-Stimulating-Factor-Tr-e.pdf. Accessed May 9, 2014
27. Murphy G, Farah B, Wong W, et al. Direct Acting Antiviral Agents for Chronic Hepatitis C Genotype 1 [Internet]. Ottawa: Canadian Agency for Drugs and Technologies in Health, 2014. http://www.cadth.ca/media/pdf/TR0007-HepC-ScienceReport-e.pdf. Accessed January 24, 2015
28. Brady B, Siebert U, Sroczynski G, et al. Pegylated interferon combined with ribavirin for chronic hepatitis C virus infection: an economic evaluation. Ottawa: Canadian Agency for Drugs and Technologies in Health, 2007
29. Bunchorntavakul C, Reddy KR. Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther 2015; 42: 258-72
30. Sarrazin C, Hezode C, Zeuzem S, et al. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012; 56 (1 Suppl): 88-100
31. Gentile I, Borgia F, Coppola N, et al. Daclatasvir: the first of a new class of drugs targeted against hepatitis C virus NS5A. Curr Med Chem 2014; 21: 1391-404
32. Bristol-Myers Squibb Canada. Daklinza (daclatasvir) tablets, 30 and 60 mg. Product Monograph. Montreal, Quebec. 2015 [Internet]. http://webprod5.hc-sc.gc.ca/dpd-bdpp/info.do?code=92992&lang=eng. Accessed October2, 2015
33. Gilead Sciences Canada Inc. Sovaldi (sofosbuvir) Product monograph. Mississauga, Ontario. 2015. http://webprod5.hc-sc.gc.ca/dpd-bdpp/item-iteme.do?pm-mp=00031317. Accessed August 9, 2015
34. Merck Canada Inc. Pegetron Product Monograph. Kirkland, Quebec. 2013 [Internet]. http://webprod5.hc-sc.gc.ca/dpd-bdpp/item-iteme.do?pm-mp=00019617. Accessed January 28, 2015
35. Hoffmann-La Roche Limited. Pegasys RBV (peginterferon alfa-2a and ribavirin) Product Monograph. Mississauga, Ontario. 2013 [Internet]. http://webprod5.hc-sc.gc.ca/dpd-bdpp/item-iteme.do?pm-mp=00021687. Accessed February 4, 2015
36. Chung RT, Davis GL, Masur H, et al. Hepatitis C Guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with Hepatitis C Virus. Hepatology 2015; 62 (3): 932-54
37. European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol 2015;63:199-236
38. Martin NK, Vickerman P, Miners A, et al. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology 2012; 55: 49-57
39. McEwan P, Ward T, Yuan Y, et al. The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States. Hepatology 2013; 58: 54-64
40. Statistics Canada. Life Tables, Canada, Provinces and Territories, 2009 to 2011 [Internet]. Ottawa. 2013. http://www.statcan.gc.ca/pub/84-537-x/84-537-x2013005-eng.pdf. Accessed February 20, 2015
41. Myers RP, Hilsden RJ, Lee SS. Historical features are poor predictors of liver fibrosis in Canadian patients with chronic hepatitis C. J Viral Hepat 2001; 8: 249-55
42. Marotta P, Feinman S, Ghent C, et al. Final Results of the Canadian POWeR (Pegetron Prospective Optimal Weight-Based Dosing Response) Program. Sustained Virologic Response (SVR) to Weight-Based Peginterferon alfa-2b + Ribavirin in a Large, Mixed, Community and Academic Observational Study [Internet]. 58th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA. 2007. http://www.natap.org/2007/AASLD/AASLD-63.htm. Accessed March 14, 2014
43. Nelson DR, Cooper JN, Lalezari JP, et al. All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase 3 Study. Hepatology 2015; 61: 1127-35
44. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370: 1993-2001
45. Swallow E, Song J, Yuan Y, et al. Comparative Efficacy and Tolerability of Daclatasvir + Sofosbuvir versus Sofosbuvir + Ribavirin for Hepatitis C Genotype 3: a Matching-Adjusted Indirect Comparison. European Association for the Study of the Liver. Vienna, Austria, 2015
46. McLernon DJ, Dillon J, Donnan PT. Health-state utilities in liver disease: a systematic review. Med Decis Mak 2008; 28: 582-92
47. Sullivan PW, Ghushchyan V. Preference-Based EQ-5D index scores for chronic conditions in the United States. Med Decis Mak 2006; 26: 410-20
48. Del Rio RA, Post AB, Singer ME. Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy. Hepatology 2006; 44: 1598-606
49. Krajden M, Kuo M, Zagorski B, et al. Health care costs associated with hepatitis C: a longitudinal cohort study. Can J Gastroenterol 2010; 24: 717-26
50. Régie de l'assurance maladie du Québec. Liste des médicaments dernière mise à jour le 24 juillet 2015 [Internet]. Québec. 2014. https://www.prod.ramq.gouv.qc.ca/DPI/PO/Commun/PDF/Liste-Med/Liste-Med/liste-med-2015-07-24-fr.pdf. Accessed August 5, 2015
51. Lachaine J, Vachon ML, Lambert-Obry V, et al. Costs Of Adverse Events Associated With Treatment Of Hepatitis C Virus Infection: An Analysis Using The Quebec Provincial Drug Reimbursement Program Database. Value Health 2014; 17: A272
52. Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies. Ottawa. 2006. https://www.cadth.ca/sites/default/files/pdf/186-EconomicGuidelines-e.pdf. Accessed August 7, 2015
53. McEwan P, Ward T, Webster S, et al. Estimating the long-Term clinical and economic outcomes of daclatasvir plus asunaprevir in difficult-To-Treat Japanese Patients chronically infected with Hepatitis C Genotype 1b. Value Health Reg Issues 2014; 3: 136-45
54. McEwan P, Ward T, Chen C-J, et al. Estimating the incidence and prevalence of chronic Hepatitis C Infection in Taiwan Using Back Projection. Value Health Reg Issues 2014; 3: 5-11
55. Townsend R, McEwan P, Kim R, et al. Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C. Value Health 2011; 14: 1068-77
56. Salomon JA, Weinstein MC, Hammitt JK, et al. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003; 290: 228-37
57. Van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-93
58. Chong CA, Gulamhussein A, Heathcote EJ, et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003; 98: 630-8
59. Stedman CA. Current prospects for interferon-free treatment of hepatitis C in 2012. J Gastroenterol Hepatol 2013; 28: 38-45
60. Federico CA, Hsu PC, Krajden M, et al. Patient time costs and out-of-pocket costs in hepatitis C. Liver Int 2012; 32: 815-25